直覺手術 (ISRG) 2012 Q3 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Ladies and gentlemen, thank you for standing by, and welcome to the Intuitive Surgical Q3 2012 earnings release conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will be given at that time. (Operator Instructions) Also, as a reminder, today's teleconference is being recorded.

    各位女士、先生,感謝您稍候,歡迎參加直覺外科(Intuitive Surgical)2012 年第三季(Q3)財報發布電話會議。此刻,所有與會者皆處於僅收聽模式。稍後我們將進行問答環節,屆時會提供相關指示。(接線員指示)另外提醒您,今日的電話會議將被錄音。

  • At this time, I would like to turn the conference call over to your host, Senior Director of Finance, Mr. Calvin Darling. Please go ahead, sir.

    現在,我想將電話會議交給本次主持人——財務資深總監 Calvin Darling 先生。先生,請開始。

  • Calvin Darling - Senior Director of Finance

    Calvin Darling - Senior Director of Finance

  • Thank you. Good afternoon, and welcome to Intuitive Surgical's third-quarter conference call. With me today we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Aleks Cukic, our Vice President of Strategic Planning.

    謝謝。各位下午好,歡迎參加直覺外科第三季電話會議。今天與我一同出席的有:總裁暨執行長 Gary Guthart;財務長 Marshall Mohr;以及策略規劃副總裁 Aleks Cukic。

  • Before we begin, I would like to inform you that comments mentioned on today's call may be deemed to contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in detail in the Company's Securities and Exchange Commission filings. Prospective investors are cautioned not to place undue reliance on such forward-looking statements.

    在開始之前,我想提醒各位,今日電話會議中的評論可能被視為包含前瞻性陳述。由於若干風險與不確定性,實際結果可能與明示或暗示的內容存在重大差異。這些風險與不確定性已在本公司向美國證券交易委員會(SEC)提交的文件中有詳細說明。提醒潛在投資人勿過度依賴此類前瞻性陳述。

  • Please note that this conference call will be available for audio replay on our website at intuitivesurgical.com on the Intuitive's Archives -- on the Audio Archive section under our Investor Relations page. In addition, today's press release has been posted to our website.

    請注意,本次電話會議將可於我們的網站 intuitivesurgical.com 進行音訊重播,位置在 Investor Relations(投資人關係)頁面下的 Audio Archive(音訊存檔)之 Intuitive Archives(存檔)區。此外,今日的新聞稿也已發布於我們的網站。

  • Today's format will consist of providing you with highlights of our third quarter results, as described in our press release announced earlier today, followed by a question-and-answer session. Gary will present the quarter's business and operational highlights. Marshall will provide a review of our third-quarter financial results. Aleks will discuss marketing and clinical highlights, then I'll provide an update to our financial forecast for 2012. And finally, we will host a question-and-answer session.

    今天的流程將先提供第三季業績重點(如同今日稍早發布的新聞稿所述),接著進行問答環節。Gary 將介紹本季的業務與營運重點。Marshall 將回顧第三季財務結果。Aleks 將說明行銷與臨床重點,之後我將更新我們對 2012 年的財務預測。最後,我們將進行問答環節。

  • With that, I'll turn it over to Gary.

    接下來,我把時間交給 Gary。

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • Thank you for joining us today. The third quarter highlighted both market strengths and headwinds. Our procedure performance came in below our expectations, driven by challenging conditions in Europe, and changes in prostate cancer detection and treatment. On the positive side, acceptance of da Vinci surgery in general and gynecologic surgery continues to grow in complex cancer procedures, benign procedures, and in single-port robotic surgery.

    感謝各位今天加入我們。第三季同時呈現市場的優勢與逆風。我們的手術量表現低於預期,主因是歐洲的艱困環境,以及前列腺癌檢測與治療方式的變化。正面來看,達文西手術(da Vinci surgery)整體的接受度,以及婦科手術在複雜癌症手術、良性手術與單孔機器人手術方面的採用,仍持續成長。

  • In the third quarter, procedure growth was challenged by continuing weakness in Europe, and acceleration in the decline of our US da Vinci prostatectomies. The prostatectomy decline appears to be driven by a combination of the U.S. Preventive Services Task Force recommendation against PSA testing, and a change in treatment recommendations for low-risk prostate cancer away from definitive treatment.

    第三季的手術量成長受到歐洲持續疲弱,以及美國達文西前列腺切除術(da Vinci prostatectomies)下滑加速的挑戰。前列腺切除術的下滑似乎是由兩項因素共同驅動:美國預防服務工作小組(U.S. Preventive Services Task Force)不建議進行 PSA 檢測的建議,以及對低風險前列腺癌的治療建議轉向避免採取根治性治療。

  • European procedure weakness appears to be driven by three underlying conditions -- broad economic pressure in Europe; sentiment behind the PSA testing recommendation from the US reflecting into Europe; and the need for increased depth in our commercial organization. As we have mentioned on prior calls, we expect economic pressure in Europe to persist for the near future. We have been investing in our European commercial organization over the past couple of quarters, and anticipate doing so for the next several.

    歐洲手術量疲弱似乎由三個根本因素驅動——歐洲整體經濟壓力;美國 PSA 檢測建議所引發的觀感延伸影響至歐洲;以及我們商業組織需要更深的配置與能力。如同我們在先前電話會議中提到的,我們預期歐洲的經濟壓力在短期內仍將持續。過去幾個季度我們已持續投資於歐洲的商業組織,並預期未來幾個季度仍會繼續投入。

  • Moving to general surgery, we experienced continued strong growth, which was multifaceted, including growth in colon and rectal surgery for cancers, as well as cholecystectomy, the latter following the introduction of Single-Site earlier in the year. Gynecology performance was solid. And like general surgery, gynecology growth was broad-based, including hysterectomy, sacrocolpopexy, and myomectomy. Aleks will provide additional procedure commentary later in the call.

    談到一般外科,我們持續經歷強勁成長,且成長來源多元,包括結腸與直腸癌症手術的成長,以及膽囊切除術(cholecystectomy);後者是在今年稍早推出 Single-Site 之後所帶動。婦科表現穩健。且如同一般外科,婦科成長也相當廣泛,包括子宮切除術(hysterectomy)、薦骨陰道固定術(sacrocolpopexy)與子宮肌瘤切除術(myomectomy)。Aleks 將在稍後的會議中提供更多手術量相關評論。

  • In Japan, system sales and procedure performance have both continued to grow, led by dVP. Two da Vinci training centers have opened this year, one at Fujita Health, and one at Tokyo Medical University, to increase in-country capacity for training Japanese surgeons.

    在日本,系統銷售與手術量表現皆持續成長,主要由 dVP 帶動。今年已新設兩座達文西訓練中心,一座位於藤田醫科(Fujita Health),另一座位於東京醫科大學(Tokyo Medical University),以提升日本國內訓練日本外科醫師的量能。

  • Turning to our operating performance for the third quarter, we sold 155 da Vinci Surgical Systems, up from 133 during the third quarter of last year. Procedures grew approximately 22% over the third quarter of 2011. Instrument and accessory revenue was $218 million, up 24% over Q3 2011. Total revenue was $538 million, up 20% over last year. Total recurring revenue grew to $306 million, up 24% from prior-year and comprising 57% of total revenue.

    接著談第三季的營運表現,我們售出 155 套達文西手術系統(da Vinci Surgical Systems),高於去年第三季的 133 套。手術量較 2011 年第三季約成長 22%。器械與配件收入為 2.18 億美元,較 2011 年第三季成長 24%。總營收為 5.38 億美元,較去年成長 20%。經常性收入總額成長至 3.06 億美元,較去年同期成長 24%,並占總營收的 57%。

  • We generated an operating profit of $259 million before non-cash stock option expense, up 21% from the third quarter of last year and representing 48% of Q3 revenue. Net income was $183 million, up 50% over last year. We ended the quarter with $2,701,000,000 in cash and investments, up $70 million from last quarter.

    在扣除非現金股票選擇權費用之前,我們的營業利益為 2.59 億美元,較去年第三季成長 21%,相當於第三季營收的 48%。淨利為 1.83 億美元,較去年成長 50%。本季末現金與投資為 27.01 億美元,較上季增加 7,000 萬美元。

  • Turning to recently launched products and those in development, in the third quarter, we continued to focus on our launches of Single-Site for cholecystectomy and Vessel Sealer. This quarter, we submitted our 510(k) for Single-Site instruments and indications for use in benign hysterectomy, and salpingo-oophorectomy. We have received FDA's questions and are encouraged by the conversation for this extension of Single-Site. We will work over the next few months to gather the data they have requested.

    談到近期推出的產品與研發中的產品,第三季我們持續聚焦於 Single-Site(用於膽囊切除術)以及 Vessel Sealer 的上市推廣。本季我們已就 Single-Site 器械與適應症(用於良性子宮切除術與輸卵管卵巢切除術〔salpingo-oophorectomy〕)提交 510(k) 申請。我們已收到 FDA 的問題,並對於就 Single-Site 延伸應用所進行的溝通感到鼓舞。未來幾個月我們將著手蒐集其所要求的資料。

  • We mentioned on our last call that we expect applications for the da Vinci Vessel Sealer to be centered on general surgery and gynecologic procedures. Uptake and customer response to the Vessel Sealer has been positive in both of these disciplines. Lastly, with regard to our da Vinci stapler, we have submitted our responses to FDA and believe that we have answered their questions. We are awaiting their response.

    我們在上次電話會議中提到,我們預期達文西 Vessel Sealer 的應用將以一般外科與婦科手術為主。在這兩個領域中,Vessel Sealer 的採用速度與客戶回饋皆為正向。最後,關於我們的達文西縫合器(da Vinci stapler),我們已向 FDA 提交回覆,並相信已回答其問題。我們正等待其回應。

  • As we enter new surgical markets and drive into new product arenas, we continue to invest in building our team, and expanding partnerships and acquiring technologies that can make a difference to robotic surgery. Given the uptake of da Vinci in general surgery, we expect to increase our sales force for emerging general surgery procedures and to increase customer training capacity. Furthermore we plan to continue investment in our sales and marketing team in Europe and our overall organization in Japan. This quarter, we added 92 people to our team, predominantly in sales manufacturing and R&D, bringing our total team to 2,192 employees.

    隨著我們進入新的外科市場並拓展至新的產品領域,我們持續投資於團隊建置、擴大合作夥伴關係,以及收購能為機器人手術帶來差異化的技術。鑑於達文西在一般外科的採用情況,我們預期將擴增銷售團隊以支援新興的一般外科手術,並提升客戶訓練量能。此外,我們計畫持續投資於歐洲的銷售與行銷團隊,以及日本的整體組織。本季我們新增 92 名員工,主要在銷售、製造與研發部門,使員工總數達到 2,192 人。

  • I will now pass the time over to Marshall, our Chief Financial Officer.

    現在我把時間交給我們的財務長 Marshall。

  • Marshall Mohr - SVP and CFO

    Marshall Mohr - SVP and CFO

  • Thank you, Gary. Our third-quarter revenue was $538 million, up 20% compared with $447 million for the third quarter of 2011, and up slightly compared to the $536 million last quarter.

    謝謝你,Gary。我們第三季營收為 5.38 億美元,較 2011 年第三季的 4.47 億美元成長 20%,並較上季的 5.36 億美元略為增加。

  • Third-quarter revenues by product category were as follows. Third-quarter instrument accessory revenue was $218 million, up 24% compared with $176 million for the third quarter of 2011, and down 3% compared with $224 million in the second quarter of 2012. The year-over-year increase in I&A was driven by procedure growth of approximately 22% in sales of our new instrument and accessory products, including Single-Site, Vessel Sealer and Firefly. The year-over-year procedure growth was led by US gynecologic procedures and US general surgery growth, partially offset by lower growth in Europe and a decrease in US dVP's.

    第三季各產品類別營收如下。第三季器械與配件(I&A)營收為2.18億美元,較2011年第三季的1.76億美元成長24%,但較2012年第二季的2.24億美元下降3%。I&A年增主要由手術量成長所帶動,約22%的成長來自我們新器械與配件產品(包括Single-Site、Vessel Sealer與Firefly)的銷售。年增的手術量成長主要由美國婦科手術與美國一般外科手術成長所帶動,但部分被歐洲較低的成長以及美國dVP手術量下降所抵銷。

  • Third-quarter 2012 US dVP procedures decreased 20% compared to the prior year. The decrease in I&A revenue compared to last quarter was primarily driven by the timing of stocking and distributor orders. Instrument and accessory revenue realized per procedure, including initial stocking orders, was approximately $1980 per procedure, which is higher than the $1950 realized in the third quarter of 2011, but lower than the $2020 realized in the second quarter of 2012. The sequential decrease was driven by the timing of instrument and accessory stocking orders associated with new system sales and the timing of distributor orders.

    2012年第三季美國dVP手術量較前一年下降20%。相較上一季I&A營收的下降,主要是由備貨與經銷商下單時點所致。每例手術實現的器械與配件營收(含初始備貨訂單)約為每例1,980美元,高於2011年第三季的每例1,950美元,但低於2012年第二季的每例2,020美元。此一連續季下降主要由新系統銷售相關之器械與配件備貨訂單時點,以及經銷商下單時點所驅動。

  • Third-quarter 2012 systems revenue of $232 million increased 17% compared with $199 million for the third quarter of 2011, and increased 1% compared with $229 million for the second quarter of 2012. We sold 155 systems in the third quarter of 2012 compared with 133 systems in the third quarter of 2011, and 150 systems in the second quarter of 2012.

    2012年第三季系統營收為2.32億美元,較2011年第三季的1.99億美元成長17%,較2012年第二季的2.29億美元成長1%。我們於2012年第三季售出155套系統,較2011年第三季的133套增加,亦高於2012年第二季的150套。

  • Our third-quarter average sales price per system was $1.48 million, an increase from the $1.46 million realized in the third quarter of 2011, and a decrease compared to the $1.53 million realized in the second quarter. ASPs include all da Vinci models, all simulators, and Firefly when configured with the system, and exclude upgrades. The decrease in ASPs compared with the second quarter of 2012 was driven by a lower proportion of dual console and simulator configurations, and lower revenue recognized on euro-denominated sales.

    第三季每套系統平均銷售價格(ASP)為148萬美元,高於2011年第三季實現的146萬美元,但低於第二季實現的153萬美元。ASP包含所有da Vinci機型、所有模擬器,以及與系統一同配置時的Firefly,並排除升級收入。相較2012年第二季ASP下降,主要由雙控制台與模擬器配置占比較低,以及以歐元計價銷售所認列的收入較低所致。

  • We sold 87 simulators during the quarter, mostly in conjunction with new system sales, compared with 121 last quarter. We sold 20 dual console systems compared to 28 in the second quarter. 34 of our third-quarter 2012 system sales involve trade-ins comprised of 26 da Vinci S's and eight standard models. 35 of our second-quarter 2012 system sales involve trade-ins comprised of 23 da Vinci S's and 12 standard models. ASPs will fluctuate quarter-to-quarter based on product, customer, and trade-in mix, as well as foreign exchange rates on direct sales to foreign customers.

    本季我們售出87台模擬器,多數與新系統銷售一併出售,較上一季的121台減少。我們售出20套雙控制台系統,較第二季的28套減少。2012年第三季系統銷售中有34筆涉及以舊換新,包含26套da Vinci S與8套標準機型。2012年第二季系統銷售中有35筆涉及以舊換新,包含23套da Vinci S與12套標準機型。ASP將因產品、客戶與以舊換新組合,以及對海外客戶直接銷售的匯率變動,而於各季間波動。

  • Service revenue increased to $88 million, up 22% compared with $72 million last year, and up 5% compared with $83 million last quarter. The growth in service revenue was primarily driven by a larger system install base.

    服務營收增至8,800萬美元,較去年7,200萬美元成長22%,較上一季8,300萬美元成長5%。服務營收成長主要由系統裝機基數擴大所帶動。

  • Total third-quarter recurring revenue comprised of instrument, accessory and service revenue, increased to $306 million, up 24% compared with the third quarter of 2011, and roughly equal to the second quarter of 2012. Recurring revenue represented 57% of total third-quarter revenue compared with 55% in the third quarter last year and 57% last quarter.

    第三季總經常性營收(由器械、配件與服務營收構成)增至3.06億美元,較2011年第三季成長24%,且與2012年第二季大致相當。經常性營收占第三季總營收的57%,相較去年第三季為55%,上一季為57%。

  • International results were as follows. Third-quarter revenue outside the US was $115 million, up 22% compared with revenue of $94 million in the third quarter of 2011, and up 14% compared with revenue of $101 million in the second quarter of 2012. Our international revenue growth is primarily driven by higher system sales into Japan. 16 da Vinci S. systems were sold into Japan during the third quarter of 2012, compared to six during the third quarter of 2011, and seven during the second quarter of 2012.

    國際市場結果如下。第三季美國以外營收為1.15億美元,較2011年第三季的9,400萬美元成長22%,較2012年第二季的1.01億美元成長14%。我們的國際營收成長主要由對日本的系統銷售增加所帶動。2012年第三季在日本售出16套da Vinci S系統,較2011年第三季的6套增加,亦高於2012年第二季的7套。

  • International instrument accessory revenue grew approximately 9% year-over-year, and decreased 17% sequentially. The changes in instrument and accessory revenue roughly followed the procedure volumes and reflect summer seasonality, a difficult European economic environment, and distributor buying patterns.

    國際器械與配件營收年增約9%,但較前一季下降17%。器械與配件營收的變動大致隨手術量而變,並反映夏季季節性、歐洲艱困的經濟環境,以及經銷商採購模式。

  • We sold 41 systems outside the United States compared with 34 in the third quarter of 2011 and 26 last quarter, reflecting higher Japanese placements. We sold 13 systems in Europe this quarter compared with 18 in the third quarter of 2011 and 13 last quarter. The decline in year-over-year European system sales reflects the difficult macroeconomic environment. Aleks will provide additional details of international system sales.

    本季我們在美國以外售出41套系統,較2011年第三季的34套及上一季的26套增加,反映日本裝機量提高。本季我們在歐洲售出13套系統,較2011年第三季的18套下降,與上一季的13套持平。歐洲系統銷售年減反映艱困的總體經濟環境。Aleks將提供更多國際系統銷售的細節。

  • Moving on to the remainder of the P&L, gross margin in the third quarter was 72.5% compared with 72.9% during the third quarter of 2011 and 72% last quarter. Our slightly higher gross margin percentage compared to last quarter resulted primarily from cost improvements made to our new products.

    接著看損益表其餘項目,第三季毛利率為72.5%,相較2011年第三季為72.9%,上一季為72%。我們相較上一季略高的毛利率,主要來自我們對新產品所做的成本改善。

  • Third-quarter 2012 operating expenses of $179 million were up 22% compared with the third quarter of 2011 and up 11% compared with the second quarter of 2012. Our higher third-quarter 2012 operating expenses resulted in a large part from the timing of non-cash stock option expenses. Beginning in 2012, we changed our stock option granting pattern, so that employees are now granted options at both February 15 and August 15, compared with only at February 15 in prior years.

    2012年第三季營業費用為1.79億美元,較2011年第三季成長22%,較2012年第二季成長11%。2012年第三季營業費用較高,很大一部分源自非現金股票選擇權費用認列時點的影響。自2012年起,我們改變股票選擇權授予模式,員工現在於2月15日與8月15日皆會獲授選擇權,而過去年度僅於2月15日授予。

  • Although approximately the same number of options were granted in each year, we recognized a higher proportion of stock option expense in the third quarter of 2012, relative to the first two quarters of 2012 and the third quarter of 2011. On a year-to-date basis, the stock option expense in 2012 is comparable to 2011. Our higher third-quarter 2012 operating expenses also reflect higher R&D project expenses and increased headcount. We added 92 employees in the quarter, including 44 employees in our commercial operations and 36 employees in product operations.

    雖然每年授予的選擇權數量大致相同,但相較2012年前兩季及2011年第三季,我們在2012年第三季認列了較高比例的股票選擇權費用。以年初至今基礎來看,2012年的股票選擇權費用與2011年相當。2012年第三季較高的營業費用亦反映較高的研發專案費用與人力增加。本季我們新增92名員工,其中商業營運新增44名、產品營運新增36名。

  • Third-quarter 2012 operating income was $211 million or 39% of sales compared with $179 million or 40% of sales for the third quarter of 2011, and $225 million or 42% of sales for the second quarter of 2012. Third quarter 2012 operating income reflected $47 million of non-cash stock compensation expense compared with $35 million for the third quarter of 2011 and $33 million last quarter.

    2012年第三季營業利益為2.11億美元,或占銷售額39%;相較2011年第三季為1.79億美元、占銷售額40%,以及2012年第二季為2.25億美元、占銷售額42%。2012年第三季營業利益包含4,700萬美元的非現金股票薪酬費用,相較2011年第三季為3,500萬美元,上一季為3,300萬美元。

  • Our effective tax rate for the third quarter was 15% compared with 32% for the third quarter of 2011 and 32% last quarter. Our lower third-quarter tax rate resulted from the release of reserves specific to tax shares where the statute of limitations has now expired, and adjustments to our 2011 provision, as we have now finalized and filed the related returns. Excluding one-time benefits, our third-quarter tax provision would have been approximately $38 million higher.

    第三季有效稅率為15%,相較2011年第三季為32%,上一季亦為32%。第三季較低的稅率,源自針對稅務股份(tax shares)之準備金回轉(因相關法定追溯期限已屆滿),以及對2011年稅務提列的調整,因我們現已完成定案並申報相關報稅表。若排除一次性利益,我們第三季的所得稅費用將約高出3,800萬美元。

  • Our net income was $183 million or $4.46 per share, compared with $122 million or $3.05 per share for the third quarter of 2011, and $155 million or $3.75 per share for the third quarter of -- for the second quarter of 2012. Excluding the one-time tax benefits, our third-quarter net income would have been $145 million or $3.54 per share.

    我們的淨利為1.83億美元,或每股4.46美元,相較於2011年第三季的1.22億美元或每股3.05美元,以及2012年第二季的1.55億美元或每股3.75美元。若排除一次性稅務利益,我們第三季的淨利將為1.45億美元,或每股3.54美元。

  • Let me quickly summarize our results for the first nine months of 2012. Procedures grew by 25%. Total revenue was $1,570,000,000, up 25% compared with $1,261,000,000 last year. The revenue increase included recurring revenue growth of 27% and an increase in systems revenue of 21%.

    我快速總結一下我們2012年前九個月的業績。手術量成長25%。總營收為15.70億美元,較去年12.61億美元成長25%。營收增加包含經常性營收成長27%,以及系統營收成長21%。

  • Year-to-date operating income was $630 million, up 27% compared with $495 million last year. Operating income included $115 million of stock-based compensation charges compared with $102 million in 2011. Net income was $482 million or $11.72 per share compared with $344 million or $8.55 per share last year. Year-to-date cash flow from operations was $597 million compared with $464 million last year.

    年初至今的營業利益為6.30億美元,較去年4.95億美元成長27%。營業利益包含1.15億美元的股票基礎薪酬費用,2011年為1.02億美元。淨利為4.82億美元,或每股11.72美元,相較於去年3.44億美元或每股8.55美元。年初至今來自營運活動的現金流量為5.97億美元,去年為4.64億美元。

  • Now moving to the balance sheet. We ended the third quarter with cash and investments of $2.7 billion, up $70 million compared with June 30, 2012. The increase was driven by $246 million of cash flows from operations, plus $38 million from the exercise of stock options, partially offset by $170 million in stock buybacks and $17 million of capital and IP purchases. We bought back 343,000 shares at an average price of $495 per share, and we have 383 million Board-authorized buybacks remaining.

    接著看資產負債表。第三季末我們的現金與投資為27億美元,較2012年6月30日增加7,000萬美元。增加主要來自2.46億美元的營運現金流,加上3,800萬美元的員工認股權行使所得,部分被1.70億美元的庫藏股回購以及1,700萬美元的資本支出與智慧財產(IP)購置所抵銷。我們以每股平均495美元回購343,000股,董事會核准的回購額度尚餘3.83億美元。

  • And with that, I'd like to turn it over to Aleks, who will go over our sales, marketing and clinical highlights.

    接下來我想把時間交給Aleks,他將說明我們的銷售、行銷與臨床重點。

  • Aleks Cukic - VP of Strategy

    Aleks Cukic - VP of Strategy

  • Thank you, Marshall. During the third quarter, we sold 155 da Vinci systems -- 114 in the United States, 13 into Europe, and 28 into rest-of-world markets. As part of the 155 system sales, 8 standard da Vinci systems and 26 da Vinci S. systems were traded in for credit against sales for new da Vinci Si systems.

    謝謝你,Marshall。第三季期間,我們售出155套達文西系統——美國114套、歐洲13套、以及其他國際市場28套。在這155套系統銷售中,有8套標準達文西系統與26套達文西S系統以折抵方式換購新的達文西Si系統。

  • We had a net 121 system additions to the installed base during the quarter, which brings to 2462 the cumulative number of da Vinci systems worldwide -- 1789 in the US, 400 in Europe, and 273 in rest-of-world markets. 79 of the 155 systems installed during the quarter represented repeat system sales to existing customers.

    本季我們的裝機基礎淨增加121套,使全球達文西系統累計裝機數達到2,462套——美國1,789套、歐洲400套、其他國際市場273套。本季安裝的155套系統中,有79套為既有客戶的重複採購。

  • In total, 139 of the 155 systems sold represented da Vinci Si or Si-e systems, which included 20 dual console systems. The 41 system sales internationally included 16 into Japan, 4 into Australia, and 3 into Belgium. The 16 systems placed in Japan establishes it as our second largest da Vinci market worldwide, with 70 placements. With the exception of Europe, our da Vinci system performance remained very solid.

    總計而言,售出的155套系統中有139套為達文西Si或Si-e系統,其中包含20套雙主控台系統。國際市場的41套系統銷售包含日本16套、澳洲4套、比利時3套。日本本次配置的16套,使其成為我們全球第二大達文西市場,累計配置達70套。除歐洲外,我們的達文西系統表現仍然非常穩健。

  • Clinically, we did not meet our procedure expectations for the quarter, achieving year-over-year procedure growth of approximately 22%. The shortfall can be attributed to two factors -- a larger than expected decline in our US dVP business, and procedure underperformance in Europe. The pressure we face within our US dVP business can be traced to both conservative PSA screening protocols and a change in treatment recommendations for low-risk cancer patients, away from definitive treatment.

    在臨床方面,我們本季未達到手術量預期,年增手術量約22%。落差可歸因於兩個因素——美國dVP業務下滑幅度高於預期,以及歐洲手術量表現不如預期。我們在美國dVP業務面臨的壓力,源自較保守的PSA篩檢流程,以及對低風險癌症患者治療建議的改變,從根治性治療轉向其他方式。

  • Our EU procedure business shortfall is a bit more complex to define, as it appears to be both macroeconomic and structural in nature, as Gary stated. With the exception of these two areas, procedure performance was solid. Growth during the quarter was led by the categories of general surgery and GYN. Procedures which included da Vinci hysterectomy; cholecystectomy; colon and rectal resections; lobectomy; endometriosis resections; sacrocolpopexies; myomectomy; mitral valve repair; and nephrectomy all displayed solid growth.

    我們在歐盟手術量業務的落差較難界定,因為如Gary所述,看起來同時具有總體經濟與結構性的因素。除這兩個領域外,手術量表現穩健。本季成長主要由一般外科與婦科(GYN)帶動。包含達文西子宮切除術、膽囊切除術、結腸與直腸切除、肺葉切除術、子宮內膜異位切除、薦骨陰道固定術、子宮肌瘤切除術、二尖瓣修補術以及腎切除術等手術量皆呈現穩健成長。

  • Recently released new products continue to do well, most notably Single-Site. Early customer feedback has been positive and our initial sales have been strong. Clinical awareness for da Vinci Single-Site cholecystectomy was very apparent at the recent American College of Surgery Conference held in Chicago. The clinical presentations that were delivered through large audiences, with both US and international surgeons participating.

    近期推出的新產品持續表現良好,尤其是Single-Site。早期客戶回饋正面,初期銷售也很強勁。在近期於芝加哥舉行的美國外科醫學會(American College of Surgery)年會上,達文西Single-Site膽囊切除術的臨床能見度非常明顯。臨床發表面向大量聽眾進行,美國與國際外科醫師皆有參與。

  • Through the third quarter, we sold Single-Site instrument and accessory kits to over 350 US customers. Our recently launched Vessel Sealer product was also favorably received at this conference, with most of the interest coming from colorectal and advanced general surgery clinicians.

    截至第三季,我們已向超過350位美國客戶銷售Single-Site器械與配件套組。我們近期推出的Vessel Sealer產品在本次會議上也獲得良好反響,且多數興趣來自大腸直腸科與高階一般外科臨床醫師。

  • This product is performing well in the field, and the feature set, specifically the articulated risk design, appears to be satisfying a strong market need. The customer adoption for both da Vinci simulator and Firefly continues to expand, with 87 customers purchasing a da Vinci simulator and 64 customers purchasing Firefly systems, as part of their initial system purchases this quarter.

    該產品在臨床現場表現良好,其功能組合——特別是可關節式腕部設計——似乎滿足了強勁的市場需求。達文西模擬器與Firefly的客戶採用持續擴大,本季在初次系統採購中,有87位客戶購買達文西模擬器,64位客戶購買Firefly系統。

  • During the quarter, several hundred robotic abstracts and papers representing a variety of surgical specialties were published within various peer-reviewed journals, while quarterly conferences produced several live da Vinci procedure transmissions, postgraduate robotic courses, podium presentations, and clinical poster sessions. Much of our early general surgery success has been within procedures that are deemed difficult to perform. Near the top of that category is low rectal cancer surgery.

    本季期間,數百篇涵蓋多種外科專科的機器人手術摘要與論文發表於各類同儕審查期刊;同時,季度會議也進行了多場達文西手術的現場轉播、研究生階段的機器人課程、口頭報告與臨床海報展示。我們在一般外科的早期成功,多集中於被認為較難執行的手術。其中名列前茅的是低位直腸癌手術。

  • In a recent edition of the Annals of Surgery, a prospective study entitled, "Impact of robotic surgery on sexual and urinary functions after fully robotic nerve-sparing total mesorectal excision for rectal cancer," describe the results of 74 da Vinci rectal resections completed at the European Institute of Oncology in Milan, Italy. Urinary and sexual functions are recognized as -- dysfunctions, excuse me -- are recognized as serious complications within rectal surgery, but have yet to be reported on robotically, which was the aim of this study. 74 patients undergoing fully robotic resection for rectal cancer were prospectively included in the study.

    在近期一期的《Annals of Surgery》中,一項前瞻性研究〈Impact of robotic surgery on sexual and urinary functions after fully robotic nerve-sparing total mesorectal excision for rectal cancer〉,描述了義大利米蘭歐洲腫瘤研究所完成的74例達文西直腸切除手術結果。泌尿與性功能障礙被認為是直腸手術中的——抱歉,是功能障礙——被認為是嚴重併發症,但先前尚未有機器人手術的相關報告,而這正是本研究的目的。研究以前瞻性方式納入74位接受全機器人直腸癌切除的患者。

  • Urinary and sexual dysfunctions affecting quality of life were assessed, with specific self-administered questionnaires, in all patients undergoing robotic total mesorectal excision. And the results were calculated using validated scoring systems and statistically analyzed. The analysis showed that the sexual function and general sexual satisfaction initially decreased one month post-surgery for erectile function and general satisfaction in men, and for arousal and general satisfaction, respectively, in women.

    針對所有接受機器人全直腸系膜切除術的患者,使用特定的自填式問卷評估影響生活品質的泌尿與性功能障礙。並以經驗證的評分系統計算結果並進行統計分析。分析顯示,性功能與整體性滿意度在術後一個月初期下降:男性在勃起功能與整體滿意度方面下降;女性則分別在性喚起與整體滿意度方面下降。

  • Subsequent testing showed that both parameters increased progressively. And at 12 months post-surgery, the values were comparable to presurgical baselines. Concerning urinary function, the grade of incontinence measured one year after intervention was consistent to presurgical measurements in both sexes.

    後續測試顯示,這兩項指標皆逐步回升。在術後12個月時,其數值與術前基準相當。就泌尿功能而言,介入治療一年後測得的失禁程度,在男女兩性中皆與術前測量一致。

  • The study conclusion was, and I quote, "Robotic total mesorectal excision allows for preservation of urinary and sexual functions." The authors went on to say that this is most likely due to their ability to perform superior wristed movements, fine dissection, coupled with the stable magnified 3-D view when working around the inferior hypogastric plexus.

    該研究的結論是,我引用原文:「機器人全直腸系膜切除術可保留泌尿與性功能。」作者進一步表示,這很可能歸因於其能夠進行更優異的腕式動作、精細剝離,並且在處理下腹神經叢周圍時,具備穩定且放大的 3-D 視野。

  • Consistent with the theme of difficult-to-perform general surgical procedures is a paper out of the University of Pittsburgh Medical Center, which recently published in the Annals of Surgery. The paper entitled, "Robot-assisted minimally-invasive distal pancreatectomy is superior to laparoscopic technique," described the technical limitations of the laparoscopic approach, and how it may limit patient eligibility and require conversion to open or hand-assist surgery to maintain patient safety.

    與「難以執行的一般外科手術」這一主題一致的是,匹茲堡大學醫學中心(University of Pittsburgh Medical Center)的一篇論文近期發表於《Annals of Surgery》。該論文題為「機器人輔助微創遠端胰臟切除術優於腹腔鏡技術」,描述了腹腔鏡途徑的技術限制,以及其可能限制病患適用性,並為維持病患安全而需要轉為開腹或手輔助手術。

  • The study compared the perioperative outcomes, 90-day morbidity and mortality of their first 30 robotic distal pancreatectomies to a historical control of 94 consecutive laparoscopic distal pancreatectomies. They reported that the post-operative length of hospital stay and rates of pancreatic fistula, blood transfusions and readmissions were not statistically different between the groups. However, for patients in the robotic group, the conversion rate to open surgery was zero, as compared to the lab group of 16%, which significantly reduced the risk of excessive blood loss.

    該研究比較了其前 30 例機器人遠端胰臟切除術與歷史對照組 94 例連續腹腔鏡遠端胰臟切除術的圍手術期結果、90 天發病率與死亡率。他們報告指出,術後住院天數以及胰臟瘻、輸血與再入院的發生率在兩組之間並無統計上差異。然而,在機器人組中,轉為開腹手術的比率為零,相較之下腹腔鏡組為 16%,這顯著降低了大量失血的風險。

  • Also of note was that more pancreatic ductal adenocarcinomas were approached robotically than laparoscopically -- 43% compared to 15%. Oncologic outcomes in these cases were superior for the robotic-assisted group, with higher rates of margin-negative resection and improved lymph node yields, for both benign and malignant lesions.

    同樣值得注意的是,以機器人方式處理的胰管腺癌比例高於腹腔鏡方式——43% 相較於 15%。在這些病例中,機器人輔助組的腫瘤學結果更佳,對於良性與惡性病灶皆呈現較高的切緣陰性切除率以及更佳的淋巴結清掃數量。

  • The author's conclusion, and I quote, "Robotic distal pancreatectomies were equivalent to laparoscopic distal pancreatectomies in nearly all measurements of outcome and safety, but significantly reduced the risk of conversion to open resection, despite a statistically greater probability of malignancy in the robotic cohort. We concluded that robotic assistants may broaden indications for minimally-invasive pancreatectomy." -- end quote.

    作者的結論是,我引用原文:「在幾乎所有結果與安全性的衡量指標上,機器人遠端胰臟切除術與腹腔鏡遠端胰臟切除術相當,但即使機器人隊列在統計上具有較高的惡性可能性,仍顯著降低了轉為開腹切除的風險。我們的結論是,機器人輔助可能擴大微創胰臟切除術的適應症。」——引文結束。

  • From time to time, we'll read critical reviews relating to the cost of robotic surgery, where the underlying comparator is usually laparoscopic or laparoscopically-assisted surgery. Some comparisons have lumped several procedures into the same analysis, labeling them all as robotic, while others have looked at each procedure individually. While it would be presumptuous to dismiss all previous analysis as incorrect, it would be accurate to point out that every procedure has its own economic profile and can only be compared accordingly.

    我們不時會讀到與機器人手術成本相關的批判性評論,其中作為比較基準的通常是腹腔鏡或腹腔鏡輔助手術。有些比較將多種手術納入同一分析並一概標示為機器人手術,另一些則逐一檢視各項手術。雖然武斷地否定所有先前分析為不正確並不恰當,但可以準確指出的是,每一種手術都有其自身的經濟特性,只能在相應的前提下進行比較。

  • In a recent edition of the Journal of Endourology, a study entitled, "Cost analysis of robotic-assisted versus hand-assisted laparoscopic partial nephrectomy, reviewed the economics for one of our largest and most successful procedures, partial nephrectomy. The aim of the study was to perform a cost comparison of three approaches to partial nephrectomy, those being open, partial nephrectomy, hand-assisted laparoscopic partial nephrectomy, and robotic partial nephrectomy.

    在近期一期《Journal of Endourology》中,一項題為「機器人輔助與手輔助腹腔鏡部分腎切除術之成本分析」的研究,回顧了我們規模最大且最成功的手術之一——部分腎切除術——的經濟性。該研究旨在比較三種部分腎切除術途徑的成本,分別為開放式部分腎切除術、手輔助腹腔鏡部分腎切除術,以及機器人部分腎切除術。

  • "The retrospective analysis evaluated costs and clinical data from 89 patients who had undergone the three surgical approaches. Baseline demographic data, patient comorbidities, nephrometry score, and perioperative outcomes were assessed. Costs and sub-costs from the operating room and hospital were evaluated using non-parametric statistical analysis.

    「這項回溯性分析評估了 89 名接受上述三種手術途徑病患的成本與臨床資料。研究評估了基線人口統計資料、病患共病、腎臟腫瘤複雜度評分(nephrometry score)以及圍手術期結果。並使用非參數統計分析評估手術室與住院的成本及其子項目成本。」

  • "Since the patient comorbidities and tumor characteristics were different in the open partial nephrectomy cohort, it was excluded from the cost comparison, thus allowing for an apples-to-apples comparison between hand-assist laparoscopic partial nephrectomy and robotic partial nephrectomy.

    「由於開放式部分腎切除術隊列的病患共病與腫瘤特徵不同,因此被排除在成本比較之外,從而使手輔助腹腔鏡部分腎切除術與機器人部分腎切除術之間得以進行同類可比的比較。」

  • "The study found no difference in overall cost between hand-assist and robotic partial nephrectomy. OR costs were higher for the robotic partial nephrectomy, because of the higher robotic capital and reusable equipment cost that outweighed the cost of disposable product for the hand-assist laparoscopic partial nephrectomy group. OR time-related costs were similar between the groups. Robotic partial nephrectomy patients had a shorter length of stay, which decreased postoperative hospital costs."

    「研究發現,手輔助與機器人部分腎切除術在總體成本上沒有差異。機器人部分腎切除術的手術室(OR)成本較高,原因在於較高的機器人資本成本與可重複使用設備成本,超過了手輔助腹腔鏡部分腎切除術組的一次性耗材成本。兩組在與手術室時間相關的成本相近。機器人部分腎切除術病患的住院天數較短,從而降低了術後住院成本。」

  • They concluded by saying, and I quote, "No difference in overall costs was found between robotic partial nephrectomy and hand-assist laparoscopic partial nephrectomy. Robot allocation, OR equipment use, and length of stay are important determinants of total cost. Further study regarding recovery and quality of life may reveal added benefits to minimally-invasive approach, and increase use in nephron-sparing surgery." -- end quote.

    他們最後總結道,我引用原文:「機器人部分腎切除術與手輔助腹腔鏡部分腎切除術在總體成本上未發現差異。機器人配置、手術室設備使用以及住院天數是總成本的重要決定因素。針對復原與生活品質的進一步研究,可能揭示微創途徑的額外效益,並提高其在保腎手術中的使用。」——引文結束。

  • This concludes my comments, and I'll now turn the time over to Calvin.

    以上是我的評論,接下來把時間交給 Calvin。

  • Calvin Darling - Senior Director of Finance

    Calvin Darling - Senior Director of Finance

  • Thank you, Aleks. I will be providing you with an update to our financial forecast for 2012, including procedures, revenues, and other elements of the income statement on a GAAP basis. I will also provide estimates of significant non-cash expenses to provide you with visibility into our expected future cash flows.

    謝謝你,Aleks。我將向各位更新我們 2012 年的財務預測,包括手術量、營收,以及依 GAAP 基礎編製的損益表其他要素。我也將提供重大非現金費用的估計,以便各位更清楚我們預期的未來現金流。

  • Starting with procedures, on our last call, we forecast procedures to grow approximately 25% to 27% from the base of approximately 360,000 procedures performed in 2011. Three quarters through 2012, our procedure growth stands at approximately 25%.

    先從手術量開始,在上次電話會議中,我們預測手術量將在 2011 年約 36 萬例的基礎上成長約 25% 至 27%。截至 2012 年前三季,我們的手術量成長約為 25%。

  • During the third quarter, we saw further pressure on our US dVP volumes and upon our overall European procedure business. As a result, we now forecast full-year 2012 da Vinci procedure volume to grow approximately 24% above our 2011 total.

    在第三季期間,我們看到美國 dVP 手術量以及整體歐洲手術業務持續承受更大壓力。因此,我們目前預測 2012 全年達文西(da Vinci)手術量將較 2011 年總量成長約 24%。

  • Moving on to revenues, on our last call, we forecast 2012 revenues to grow between 20% and 23% above our 2011 revenue of $1.76 billion. As we enter the fourth quarter, we are now able to refine our guidance to the upper half of this range.

    接著談營收,在上次電話會議中,我們預測 2012 年營收將較 2011 年的 17.6 億美元成長 20% 至 23%。隨著我們進入第四季,我們現在能將指引進一步收斂至該區間的上半部。

  • Now, turning to non-cash expenses, we continue to expect non-cash stock compensation to fall within a range of between $152 million and $156 million for the year. Through three quarters of this year, $115 million of stock compensation has been recognized, and all of the quarterly timing differences related to a revised 2012 employee grant process have cycled through. The Q4 portion of total 2012 option expense should follow historical patterns.

    現在談非現金費用,我們仍預期全年非現金股票薪酬將落在 1.52 億至 1.56 億美元的區間內。截至今年前三季,已認列 1.15 億美元的股票薪酬,且與修訂後 2012 年員工授予流程相關的所有季度時間差異都已反映完畢。2012 年第四季占比的期權費用應會遵循歷史模式。

  • Now, turning to other income. On our last call -- operating income. On our last call, we forecast operating income to fall within a range of between 39% and 40% of net revenue. Now, based upon the impact of recent material cost reductions and expense timing, we expect operating income to come in at the high end of the range at about 40% for the year.

    接著談其他收入。在上次電話會議——營業利益。在上次電話會議中,我們預測營業利益將落在淨營收的 39% 至 40% 區間。現在,基於近期材料成本下降的影響以及費用認列時點,我們預期全年營業利益將落在區間高端,約為 40%。

  • We continue to expect other income, which is mainly comprised of interest income to total between $16 million and $17 million for the year. With regard to income tax, our Q3 reported tax rate of 15% reflected a discrete benefit related to releasing reserves for tax years where the statutes of limitations have expired. This discrete item favorably impacted Q3 but will not impact Q4. We continue to expect the Q4 tax rate to be approximately 31% of pre-tax income, which does not assume any reinstatement of the R&D tax credit.

    我們仍預期全年其他收入(主要由利息收入構成)合計將介於 1,600 萬至 1,700 萬美元。就所得稅而言,我們第三季報告的 15% 稅率反映了一項一次性利益,與釋放已逾追溯時效之稅務年度的準備金相關。這項一次性項目對第三季有正面影響,但不會影響第四季。我們仍預期第四季稅率約為稅前所得的 31%,其中不假設研發(R&D)稅額抵減的任何恢復。

  • Going forward into 2013, we expect to see a gradual reduction in rate to a range of between 29% and 31%. Also looking into 2013, the medical device tax is scheduled to become effective on January 1. Based upon our 2012 regional and product mix, we would estimate the tax to equate to roughly 1.1% of our net consolidated revenue. We would plan to record the expense as a component of cost of sales. We estimate that our share count for calculating EPS in Q4 2012 will be roughly flat to Q3 at approximately 41.1 million shares.

    展望 2013 年,我們預期稅率將逐步下降至 29% 至 31% 的區間。同樣展望 2013 年,醫療器材稅預計將於 1 月 1 日生效。根據我們 2012 年的區域與產品組合,我們估計該稅額約相當於我們合併淨營收的 1.1%。我們計畫將該費用列為銷貨成本的一部分。我們估計 2012 年第四季用於計算 EPS 的流通股數將與第三季大致持平,約為 4,110 萬股。

  • That concludes our prepared remarks. We will now open the call to your questions.

    以上為我們準備好的發言。接下來我們將開放提問。

  • Operator

    Operator

  • (Operator Instructions) David Lewis, Morgan Stanley.

    (接線員指示) 摩根士丹利的 David Lewis。

  • David Lewis - Analyst

    David Lewis - Analyst

  • Gary or Aleks or anyone for that matter, just thinking about the third quarter from a macro perspective, it looks like the third quarter is a lot like the second quarter. We saw significant Japan strength and US decline novo system strength offset by Europe, and we saw dVP US and OUS weakness offset, obviously, by dVH as well as some general surgery improvements.

    Gary、Aleks 或任何人都可以回答;從總體環境角度來看第三季,第三季看起來很像第二季。我們看到日本顯著走強、而美國下滑;novo 系統的強勁抵消了歐洲的影響;同時我們也看到 dVP 在美國及美國以外(OUS)的疲弱,顯然被 dVH 以及一些一般外科的改善所抵消。

  • So, do you sort of have any sense the fourth-quarter guidance sort of implies stable trends on procedures with the third quarter? Do you have any sense the balance of these positive and negative forces, how many quarters you think this could persist?

    所以,你們是否覺得第四季指引某種程度上意味著手術量的趨勢會與第三季保持穩定?你們對這些正負力量的平衡是否有任何看法,覺得這種情況可能會持續多少個季度?

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • Hi David -- Gary. You know, it's pretty hard to call US prostatectomy. That's, as you know, more an issue of medical management and watchful waiting than it is a change in imaging surgery versus other kinds of surgery.

    嗨 David——我是 Gary。你知道,美國的前列腺切除術其實很難預測。如你所知,這更多是醫療管理與「觀察等待」的問題,而不是影像手術相較於其他類型手術的改變。

  • So we don't have a crystal ball as to where that procedure is going to go over time. The data we look at is probably pretty similar to the data that you look at, in terms of where PSA testing is taking us.

    因此,對於該手術量隨時間的走向,我們也沒有水晶球。就 PSA 檢測帶來的影響而言,我們看的資料大概也和你看的資料相當類似。

  • On the upside, I think the things that are growing, we can measure a good interest from our customers. We can measure sales force activity. That tends to be a little bit more in our camp versus out in the world. So, on the downside, pretty tough to call on the upside. We can look at the activities that we can influence and feel pretty confident about the things that we can do.

    在正面方面,我認為對於正在成長的項目,我們可以衡量客戶的高度興趣。我們也可以衡量業務團隊的活動。這些相對更在我們可掌控的範圍內,而不是外部環境。所以在負面方面很難預測;在正面方面,我們可以看我們能影響的活動,並對我們能做的事情相當有信心。

  • David Lewis - Analyst

    David Lewis - Analyst

  • And then, Gary, just following up on one of those key catalysts, which obviously is single incision, I don't know if I caught it on the call but, could you sort of confirm whether SILS has sort of moved into your third-largest procedure for the Company?

    另外,Gary,延續其中一個關鍵催化因素——顯然是單孔切口——我不確定我是否在電話會議中聽到;你能否確認一下,SILS 是否已經成為公司第三大手術類別?

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • We have talked about before that cholecystectomy as a total procedure of all types multi-port and Single-Site together combined is the third. Single-port on its own is not.

    我們之前談過,膽囊切除術作為一個總手術類別——包含所有類型,多孔與 Single-Site 合併——是第三大。單孔本身並不是。

  • Calvin Darling - Senior Director of Finance

    Calvin Darling - Senior Director of Finance

  • It's important to note that, as a reminder, of course, it's a distant third. I mean, you have hysterectomy; you have prostatectomy; and you have cholecystectomy. And so you have other procedures that are sort of in the general neighborhood procedures, such as partial nephrectomy and sacrocolpopexy and others. So it is indeed third, but as a reminder, it is a distant third.

    需要提醒的是,當然它是「遙遠的第三名」。也就是說,你有子宮切除術;你有前列腺切除術;然後你有膽囊切除術。此外還有一些手術大致在相近的量級,例如部分腎切除術、薦骨陰道固定術(sacrocolpopexy)以及其他。所以它確實是第三,但再次提醒,它是遙遠的第三名。

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • There's one more difference that's worth pointing out is that, unlike prostatectomy and hysterectomy, cholecystectomy can be an entry point into a clinical pathway for somebody who wants to end somewhere else. And so those procedures can be a little more volatile.

    另外還有一個值得指出的差異:不同於前列腺切除術與子宮切除術,膽囊切除術可能是某些人進入臨床路徑的切入點,之後想要走向其他手術。因此這些手術量可能會更具波動性。

  • David Lewis - Analyst

    David Lewis - Analyst

  • And then, Gary, just one quick one, I apologize for two or three questions. But you talked about an increase in spending for both US general surgery, and potentially, I would imagine, if you're going to go after Europe and change structurally how you're selling it, there could be increased expense. Could you help us sort of frame those relative expenses versus other very significant sales investments you've made, perhaps the 2010 significant investment in the US?

    然後,Gary,再一個很快的問題;抱歉我問了兩三個。你提到在美國一般外科的支出會增加;而且我想像如果你們要在歐洲發力並在結構上改變銷售方式,費用也可能增加。你能否協助我們框架化這些相對費用,並與你們過去做過的其他非常重大的銷售投資相比,例如 2010 年在美國的重大投資?

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • Yes, this won't quite be the same scale. It's a little bit more targeted. So, in Europe, it's really filling open headcount in the field, and investing a little bit more in the back office, in terms of clinical trials and other types of marketing investments, economic analyses and so on. So that's kind of what the European side looks like. On the general surgery side, it will be general surgery-focused expertise and depth.

    是的,規模不會到那麼大。會更偏向精準投放。因此在歐洲,主要是補齊前線的空缺人力編制,並在後勤端多投入一些,例如臨床試驗與其他類型的行銷投資、經濟分析等等。這大致就是歐洲端的樣貌。在一般外科端,則會是聚焦一般外科的專業能力與深度。

  • David Lewis - Analyst

    David Lewis - Analyst

  • Great. Thank you very much.

    很好。非常感謝。

  • Operator

    Operator

  • Ben Andrew, William Blair.

    William Blair 的 Ben Andrew。

  • Ben Andrew - Analyst

    Ben Andrew - Analyst

  • Gary, can you break down the procedure growth for us between the US, Europe and ROW?

    Gary,你能否為我們拆解一下手術量成長,在美國、歐洲與其他地區(ROW)之間的分布?

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • I'll turn it to Calvin.

    我把問題交給 Calvin。

  • Calvin Darling - Senior Director of Finance

    Calvin Darling - Senior Director of Finance

  • Right. So the procedure growth, I'll find a -- excuse me. Go ahead.

    好的。關於手術量成長,我找一下——不好意思。你先說。

  • Aleks Cukic - VP of Strategy

    Aleks Cukic - VP of Strategy

  • Total procedure growth quarter -- year-over-year is 22%. And then what we said was that the procedure growth outside of the US year-over-year was 9%.

    本季手術量年增率為 22%。另外我們提到,美國以外地區的手術量年增率為 9%。

  • Ben Andrew - Analyst

    Ben Andrew - Analyst

  • Okay. So was the US close to around 30? It wouldn't be that high.

    好的。所以美國大概接近 30% 嗎?應該不會那麼高。

  • Calvin Darling - Senior Director of Finance

    Calvin Darling - Senior Director of Finance

  • Yes, I mean, you could probably back into it on your models there. But again, worldwide, we're looking at about 22% for Q3, 25% on a year-to-date basis. And included in those numbers would be a decline in the US dVP volume that Marshall mentioned, of 20% on a quarter basis, and 14% on a year-to-date basis. And so I think kind of what it implies is that if the US stayed flat from year-to-year, the worldwide growth would have been about 26% in Q3 and 28% on a year-to-date basis.

    是的,我的意思是,你大概可以用你的模型倒推。但再次強調,全球來看,我們第三季約 22%,年初至今約 25%。這些數字包含 Marshall 提到的美國 dVP 量下滑:以單季來看下滑 20%,年初至今下滑 14%。因此我認為這暗示的是:如果美國年對年持平,那麼全球成長在第三季大約會是 26%,年初至今大約會是 28%。

  • Ben Andrew - Analyst

    Ben Andrew - Analyst

  • Right. I guess what I'm getting at is, dVP down 20% in the US. If you are on a base of 75,000 cases, for '11, if that's down 20% full-year, you're talking something in the low 60,000 cases, negative 15,000 at the most -- 12,000 to 15,000. If dVH is growing [60,000], and COLI is adding [10,000] and all the other stuff is adding another [30,000 -- 40,000 -- 50,000], you end up with robust procedure growth in the United States.

    了解。我想我想問的是,美國 dVP 下滑 20%。如果你以 2011 年 75,000 例為基礎,若全年下滑 20%,你談的是 60,000 多例,最多減少 15,000 例——大概 12,000 到 15,000。如果 dVH 成長 [60,000],而 COLI 增加 [10,000],其他所有項目再增加 [30,000 -- 40,000 -- 50,000],那麼美國的手術量成長就會相當強勁。

  • And the real evidence of a problem is obviously Europe, which is macro and some concern about obviously dVP. But at some point, dVP has to bottom. And so the question becomes, is there sort of a structural level of prostatectomy that we can think about, where this will shake out over the course of, call it, six, eight quarters, and we'll end up at maybe a rate of 50,000 dVPs in the US. Does that make sense?

    而真正顯示問題的證據顯然在歐洲,那是總體環境因素,另外也有對 dVP 的一些擔憂。但在某個時間點,dVP 必須觸底。所以問題變成:是否存在一個我們可以思考的前列腺切除術結構性水準,讓它在接下來大約六到八個季度內逐步落定,最後美國 dVP 的量可能落在每年 50,000 例左右。這樣說有道理嗎?

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • The flow of your argument makes sense. I think that Calvin may argue with you about some of the numbers, just to make sure that you tied them out right. But the flow -- generally speaking, the flow makes sense.

    你的論點脈絡是合理的。我想 Calvin 可能會就其中一些數字跟你討論一下,主要是為了確認你把它們對得上。但整體的脈絡——一般來說,這個脈絡是合理的。

  • Calling that number of kind of what the baseline number of a prostatectomy is in the US is hard to do. We've seen some analysis out there that's probably similar to the kinds of analysis that you've seen. And I think we're just going to have to see where that base establishes itself.

    要說在美國前列腺切除術的「基準數字」大概是多少,其實很難。我們看到外面有一些分析,可能跟你看到的那類分析差不多。我想我們只能再觀察,看看那個基準會落在哪裡。

  • I mean I think there are a couple of things that argue for a base. One of them is that prostate cancer, the highest cure rate will come from a surgery, not from a medical management. And the other thing that we know is that over time, watchful waiting patients, some fraction of them, usually a majority of them, will converge to definitive treatment over time. So, I think both of those things will argue for finding the floor. And what exactly that floor level is, we're just going to have to wait and see.

    我的意思是,我認為有幾個因素支持會存在一個基準。其中之一是,前列腺癌最高的治癒率會來自手術,而不是藥物/內科管理。另外我們也知道,隨著時間推移,採取觀察等待(watchful waiting)的病人,其中一部分——通常是多數——最終會逐步轉向接受確定性治療。所以,我認為這兩點都支持去找出那個底部。至於那個底部到底在哪個水準,我們只能再等等看。

  • Marshall Mohr - SVP and CFO

    Marshall Mohr - SVP and CFO

  • Yes, but I think, Ben, the central theme of your thesis there is accurate. And that is, if you look outside of those two areas, US dVP and the European weakness, the remainder of the procedure business was very strong year-to-date and for the quarter.

    是的,但我認為,Ben,你那個論點的核心主題是正確的。也就是說,如果你把美國 dVP 以及歐洲疲弱這兩塊拿掉,其餘的手術量業務在年初至今以及本季都非常強勁。

  • Ben Andrew - Analyst

    Ben Andrew - Analyst

  • Okay. And I'll sneak in one more as well. If you look at Japan, we've done some calls recently, and it sounds as though the Japanese government has authorized funding for about 150 systems. And our sources were sort of indicating that that could come into play by the end of '13 and certainly [16] in the third quarter is -- goes a long way towards that.

    好的。我也再補充一個。如果看日本,我們最近做了一些訪談/電話會議,聽起來日本政府已核准為大約 150 套系統提供資金。而我們的消息來源大致指出,這可能在 2013 年底前開始發酵,而當然第三季的 [16] ——對此是很大的推進。

  • Is that consistent with sustaining this sort of a [16] or a pretty substantial rate? And is that a reasonable target for an installed base kind of going out of '13? Thanks.

    這樣是否與維持這種 [16] 或相當可觀的速度一致?而這是否是對 2013 年底裝機基數的一個合理目標?謝謝。

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • Yes, I don't think we're ready to size the total market opportunity. And I think that system sales by themselves are going to be lumpy quarter-to-quarter and I would expect some lumpiness. Long-term, we're really excited about the Japanese market opportunity. The key opinion leaders, the people we've talked to on the ground, are excited about robotic surgery, and we think it will build. And that's another area of investment. But again, kind of calling the specifics is not something we're prepared to do.

    是的,我們還沒有準備好去估算整體市場機會的規模。而且我認為單看系統銷售,本來就會在季度之間呈現不均勻(lumpy),我也預期會有些波動。長期來看,我們對日本市場機會非常興奮。關鍵意見領袖、以及我們在當地接觸到的人,都對機器人手術感到興奮,我們認為它會逐步建立起來。這也是另一個投資領域。但同樣地,要去點出具體數字並不是我們目前準備要做的事。

  • Marshall Mohr - SVP and CFO

    Marshall Mohr - SVP and CFO

  • Yes, I think there's just one caveat that's worth mentioning is, as a reminder, we have one national reimbursement, which is prostatectomy. There are ways for, as evidenced by the activities prior to that national reimbursement, that hospitals can go through, let's call them, a one-off basis or a checklist basis, where they can apply for certain levels of reimbursement on other procedures.

    是的,我想有一點提醒值得一提:作為提醒,我們目前只有一項全國性給付(reimbursement),也就是前列腺切除術。如同在取得該全國性給付之前的活動所顯示的,醫院仍有一些方式——我們姑且稱之為一次性(one-off)或依清單(checklist)——可以就其他手術申請某些層級的給付。

  • But from a national perspective, we are really in this environment where we are working within prostatectomy primarily, and then there may be a few other procedures that get worked in on a one-off basis. So that's the environment we're in for a little while.

    但從全國層面來看,我們確實處在這樣的環境:主要是在前列腺切除術的框架下運作,然後可能有少數其他手術以一次性的方式被納入。所以這就是我們接下來一段時間所處的環境。

  • Calvin Darling - Senior Director of Finance

    Calvin Darling - Senior Director of Finance

  • Yes, the next scheduled pass that procedures being added to the reimbursement list would be April of 2014 for a general systemwide reimbursement.

    是的,下一次預定把手術項目新增到給付清單的時間點,將是 2014 年 4 月,屬於一般性的、系統性(systemwide)的給付。

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • Based on the way that MHLW runs.

    依照 MHLW 的運作方式。

  • Ben Andrew - Analyst

    Ben Andrew - Analyst

  • Okay, thank you.

    好的,謝謝。

  • Operator

    Operator

  • Tycho Peterson, JPMorgan.

    JPMorgan 的 Tycho Peterson。

  • Tycho Peterson - Analyst

    Tycho Peterson - Analyst

  • Thanks for taking the question. First question maybe on COLI. Wondering if you could just give us a little bit of a breakdown as to how much of the COLI uptake is Single-Site versus multi-arm? And are you starting to see COLI drive system placements?

    謝謝讓我提問。第一個問題可能是關於 COLI。想請你們稍微拆解一下,COLI 的採用中有多少是 Single-Site、多少是多臂(multi-arm)?另外,你們是否開始看到 COLI 帶動系統裝機?

  • Calvin Darling - Senior Director of Finance

    Calvin Darling - Senior Director of Finance

  • You know, I think we're not prepared to break out what that mix is. And honestly, I think that the important message here is that -- is just to really look at this structurally. You have general surgeons who don't have a lot of robotic experience going in. And so they are going to work through various procedures to some level, to make sure that they have a good understanding of the X's and O's of the system.

    你知道的,我想我們還沒準備好把那個組合比例拆出來。坦白說,我認為這裡更重要的訊息是——要從結構面來看。你會有一些沒有太多機器人經驗的普外科醫師開始進入。因此他們會先透過各種手術做到某個程度,以確保他們對系統的基本操作與要領有良好的理解。

  • And then, what is today a general multi-port cholecystectomy, the expectation is that those move into Single-Site. So there will be a relationship. And I think trying to call it at any given time is probably a -- I don't know how meaningful that is. But, collectively, as we said, it is the third-largest procedure.

    接著,今天一般的多孔(multi-port)膽囊切除術,預期會逐步轉向 Single-Site。所以兩者會有關聯。而我認為在任何特定時間點去硬要判斷,可能——我不確定那有多大意義。但整體而言,如我們所說,這是第三大手術量。

  • Now we -- I think the way we would categorize the importance of procedures as they relate to new system placements, it's hard to tease out what is cholecystectomy and what is general surgery. Because, to Gary's earlier comments, sometimes cholecystectomy is not the end point which the general surgeons are trying to get to. And so it becomes one of many procedures that they see in their armamentarium over time.

    另外,我想我們在評估各項手術對新系統裝機的重要性時,很難把「膽囊切除術」和「普外科」清楚拆開。因為如 Gary 先前的評論所說,有時候膽囊切除術並不是普外科醫師想要達到的終點。因此它會成為他們隨時間推移在手術工具箱中看到的眾多手術之一。

  • And so, it's really hard to say what the -- what evidence we have at this point that it's COLI-specific that is driving the system. But there is definite evidence that general surgeons are becoming more and more important to system placements.

    所以,很難說我們目前有哪些證據顯示是「COLI 特定」在帶動系統。但確實有明確證據顯示,普外科醫師對系統裝機正變得越來越重要。

  • Tycho Peterson - Analyst

    Tycho Peterson - Analyst

  • And then in your commentary, you talked about additional indications for Single-Site -- benign hysterectomy and nephrectomy. Can you just talk about how you think about those opportunities? And then how much you want to push through Single-Site versus, at some point, is it logical to introduce a new system?

    另外在你們的評論中,你們談到 Single-Site 的額外適應症——良性子宮切除術與腎切除術。能否談談你們如何看待這些機會?以及你們想在 Single-Site 上推進到什麼程度;或者在某個時間點,引入一個新系統是否更合乎邏輯?

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • Yes. On the first side, we think that hysterectomy is a patient population that sets up well for a single-port robotic approach. And we've gotten good feedback from customers in Europe and the US that that's something worth pursuing. And so that's been our next procedure -- that and nephrectomy.

    是的。第一點,我們認為子宮切除術的病人族群很適合採用單孔的機器人手術方式。我們也從歐洲與美國的客戶那裡得到不錯的回饋,認為這值得投入。因此那就是我們下一個手術——以及腎切除術。

  • We'll see -- in terms of what happens next after Single-Site, we'll continue to invest in instrumentation that makes sense in that platform and in indications. I don't think that will be the last stopping point in terms of an indication for Single-Site as we go forward. And as always, we continue to invest in technologies that can make things more capable. And we invest in tissue interaction technologies. We invest in patient access, smaller ports and different ways to get into the body. And with regard to Single-Site, we'll continue to do that.

    至於 Single-Site 之後會發生什麼——我們會持續在這個平台上投資合理的器械與適應症。我不認為就適應症而言,Single-Site 會是我們往前走的最後一站。而且一如既往,我們會持續投資能讓系統更有能力的技術。我們投資於組織交互作用(tissue interaction)技術。我們投資於病人進入(patient access)、更小的穿刺孔,以及不同的進入人體方式。而就 Single-Site 而言,我們也會持續這麼做。

  • Calvin Darling - Senior Director of Finance

    Calvin Darling - Senior Director of Finance

  • Yes. I think the way we think about, for example, the Single-Site in GYN or benign hysterectomy is, if you think about the way we've always described the market, there is a level of complexity that was inherent in our target for hysterectomy -- both benign, complex benign, as well as malignant.

    是的。我想我們看待例如在婦科(GYN)或良性子宮切除術上的 Single-Site 的方式是:如果你回想我們一向如何描述市場,在我們鎖定的子宮切除術目標中,本來就存在一個複雜度層級——包含良性、複雜良性,以及惡性。

  • And so, there's a subsegment of the market that is, by definition, if you will, relatively less complex or simple. It seems like a very good area for us to apply some resources and see if this is indeed something we can access with new technology (multiple speakers), which is the approach.

    因此,市場中有一個子區隔,按定義來說,相對沒那麼複雜、或更簡單。看起來這是一個非常適合我們投入一些資源、並觀察是否確實能透過新技術(多位發言者)切入的領域,這就是我們的做法。

  • Tycho Peterson - Analyst

    Tycho Peterson - Analyst

  • Okay. And then just one last one because I'm sure we'll all get the question. In terms of the stapler, I mean, based on your interactions with FDA, are you still thinking this could come by year-end? Or should we think about stages next year? Just how do we think about timing there?

    好的。然後最後一個問題,因為我確定大家都會被問到。關於縫合器(stapler),我是說,基於你們與 FDA 的互動,你們仍然認為年底前有機會推出嗎?還是我們應該把它視為明年的分階段推進?在時程上我們該怎麼看?

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • You know, it's always hard to predict exactly timing on these things and so I won't. We've had a healthy conversation with FDA. We've understood their questions. I think that we've provided answers that make sense. And we'll let you know what happens thereafter.

    你知道,這類事情的確切時程總是很難預測,所以我不會做預測。我們與 FDA 進行了良好的溝通。我們理解了他們的問題。我認為我們已提供了合理的回覆。之後的進展我們會再告訴各位。

  • Tycho Peterson - Analyst

    Tycho Peterson - Analyst

  • Okay. Thank you.

    好的。謝謝。

  • Operator

    Operator

  • Lennox Ketner, Bank of America Merrill Lynch.

    美國銀行美林(Bank of America Merrill Lynch)的 Lennox Ketner。

  • Lennox Ketner - Analyst

    Lennox Ketner - Analyst

  • Thanks so much for taking the question. First question, just it sounds like there's a lot -- you're seeing a lot of good momentum in Japan. I'm wondering if you could just comment on what Japan contributed to either overall procedure growth in the quarter or to the 9% international growth?

    非常感謝讓我提問。第一個問題,聽起來你們在日本看到很強的動能。我想請你們評論一下,日本在本季整體手術量成長、或在 9% 的國際成長中,貢獻大概是多少?

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • Just in a broad brush, it's growing nicely off a very small base. So in-country, we're delighted with the growth rate; in terms of total contribution to the overall, it's probably not a material contribution.

    概括來說,它是在非常小的基期上有不錯的成長。所以在當地,我們對成長率很滿意;但就對整體的總貢獻而言,可能並不具重大影響。

  • Lennox Ketner - Analyst

    Lennox Ketner - Analyst

  • Okay. And then, just to go back to Europe, Gary, you talked about the fact that it's partly the macro environment and partly structural, which it sounds like you're working to address some of the structural issues. But I'm wondering if you could just give a little more detail on what those structural issues are?

    好的。然後回到歐洲,Gary,你提到部分是總體環境、部分是結構性因素,而聽起來你們正在處理一些結構性問題。但我想請你再多提供一些細節,這些結構性問題具體是什麼?

  • From my conversations with some European physicians, it sounds like two of the challenges over there are ones that in some countries, there are per diem reimbursement systems, which maybe makes the length of stay reduction less valuable upfront; but then also, just the fact that there's less competition amongst hospitals. Are those kind of the two main structural issues? Or is there something I'm missing there that you guys are working to address?

    從我與一些歐洲醫師的對話來看,那邊的兩個挑戰是:在某些國家採用按日(per diem)的給付制度,可能使得縮短住院天數在一開始的價值沒那麼明顯;另外,醫院之間的競爭也比較少。這兩點是否就是主要的結構性問題?還是我漏掉了你們正在處理的其他因素?

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • You know, I think there are a couple of things. One of the structural things is just open territories on our side and making sure we have the right number of sales people in the various countries. And we can run that against internal metrics. So it's a pretty simple one. And the solution there is to make sure that we're fully staffed.

    你知道,我想有幾件事。其中一個結構性因素是我們這邊的空缺區域(territories),以及確保在各國配置足夠且合適的業務人員數量。我們可以用內部指標來衡量。所以這其實相當單純。解方就是確保我們的人力配置到位。

  • The second thing or more along the lines you've discussed, although I described them a little bit differently. I think -- it's not really that a single-payer system is not capable or interested in adopting a da Vinci surgery; we've seen Japan's single-payer system has been moving pretty quickly. Sweden has a single-payer system that has moved quickly. So it isn't the act of being a single-payer.

    第二點比較接近你剛才提到的方向,雖然我會用稍微不同的方式描述。我認為——並不是單一支付者制度就無法或不願意採用達文西手術;我們看到日本的單一支付者制度推進得很快。瑞典也有單一支付者制度,而且推進很快。所以問題不在於是否為單一支付者。

  • It's more making sure that the conversations with government-run hospitals around both economic value and clinical data are put into forms that they can accept, and we can match their timelines. You're absolutely right with regard to systems that are using per diem, that that's a real challenge for hospitals to adopt da Vinci surgery.

    更重要的是,確保我們與政府經營的醫院在經濟價值與臨床數據方面的溝通,能以他們可接受的形式呈現,並且我們能配合他們的時程。你提到採用按日(per diem)制度的系統,確實會讓醫院採用達文西手術面臨很大挑戰,這點你說得完全正確。

  • We see per diem systems being challenged in favor of DRGs in a lot of different places not only for da Vinci. I think the trend is away from per diem, not towards it. And so I don't see that as systemic across all of your really in-pockets.

    我們看到許多地方的按日(per diem)制度正受到挑戰,並逐步轉向 DRG(診斷關聯群)制度,這不僅僅是因為達文西。我認為趨勢是遠離按日給付,而不是走向它。因此我不認為這會在你們所說的所有「口袋市場」(in-pockets)中都成為系統性的問題。

  • Lennox Ketner - Analyst

    Lennox Ketner - Analyst

  • Okay, that's very helpful. Thanks.

    好的,這非常有幫助。謝謝。

  • Operator

    Operator

  • Lawrence Keusch, Raymond James.

    Raymond James 的 Lawrence Keusch。

  • Lawrence Keusch - Analyst

    Lawrence Keusch - Analyst

  • Just to pick up on that question, could you talk a little bit about perhaps where you are seeing some of the procedure pressures within Europe? Is it more directed at Southern Europe? And just really trying to get a sense of whether anything is changing out there.

    延續剛才的問題,你們能否談談在歐洲哪些地方看到手術量的壓力?是否比較集中在南歐?我主要想了解那邊是否有任何變化。

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • You see capital pressure in southern Europe absolutely. Procedure pressure is a little bit less targeted directly with Southern versus Northern, and so it moves around a little bit.

    南歐確實存在資本支出壓力。至於手術量壓力,並沒有那麼明確地只針對南歐相對於北歐,因此會有些移動與變化。

  • (multiple speakers) Go ahead.

    (多位發言者)請說。

  • Calvin Darling - Senior Director of Finance

    Calvin Darling - Senior Director of Finance

  • So if you looked at -- then again, I think it's -- it almost takes even a little perhaps a derivative deeper. So if you looked at environments like public hospitals in France, let's say, versus clinics in France and/or private clinics in other parts of Europe, it becomes probably more akin to those comparisons than it does just individual countries.

    所以如果你看——我想這幾乎還需要再往下拆一層。例如比較法國的公立醫院環境,與法國的診所以及/或歐洲其他地區的私立診所,這樣的對比可能比單純以國家來區分更貼近實際。

  • And we've had strength in Germany over -- not this particular quarter, but in the past two years, we've called out Germany as having a lot of strength. This is the first time we've called out Belgium in probably a few -- probably a year-and-a-half. So it seems like it's rotating through various countries, but it's probably more consistent with the public versus private.

    而且我們在德國過去——不是這一季,但在過去兩年——一直點名德國表現很強。這大概是我們在幾——大概一年半以來第一次點名比利時。所以看起來是在不同國家之間輪動,但可能更一致的差異在於公立與私立。

  • Lawrence Keusch - Analyst

    Lawrence Keusch - Analyst

  • Okay, that's helpful. And I just had two other quick ones. As you noted, benign hysterectomy and nephrectomy for Single-Site -- how dependent on -- in getting into those procedures, how dependent is it on the need for new instrumentation? And if so, what might be the timing on that?

    好的,這很有幫助。我還有另外兩個簡短問題。如你們提到的,Single-Site 的良性子宮切除術與腎切除術——在切入這些手術時,對於需要新器械的依賴程度有多高?如果需要,新器械的時程大概會是什麼?

  • And then lastly, you utilized cash this quarter to buy back stock. You still have a lot. So, again, if you could just remind us of the general uses of cash?

    最後,你們本季用現金回購股票。你們手上仍有很多現金。所以,能否再提醒我們現金的一般用途有哪些?

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • You know, on the issue of Single-Site, as we've said before, we've just submitted and received our first round of questions from FDA on the extension of our indications for Single-Site into hysterectomy and oophorectomy. I think there that we have good, as you know, good momentum in hysterectomy. And I think that, I think it goes into a set of surgeons who are interested in robotic surgery, and towards a segment of the patient population that would be interested in cosmesis and return to full function.

    關於 Single-Site 的議題,如同我們之前說過的,我們剛提交了 Single-Site 適應症延伸至子宮切除術與卵巢切除術的申請,並已收到 FDA 第一輪的問題。我認為在子宮切除術方面,我們如你所知有很好的動能。我也認為這會切入一群對機器人手術有興趣的外科醫師,以及一個對外觀(cosmesis)與恢復至完全功能有興趣的病患族群。

  • So we're excited about that. I think it will make some sense. We're in the early stages of our interactions with FDA. How long that will take, it's very tough to predict and so we won't.

    所以我們對此感到興奮。我認為這會是合理的方向。我們與 FDA 的互動仍在早期階段。需要多久時間很難預測,所以我們不會做預估。

  • Calvin Darling - Senior Director of Finance

    Calvin Darling - Senior Director of Finance

  • Yes, as far as the instruments, Larry, I would say the -- which is pretty consistent with the way we have approached new markets and new procedure targets, where we have a good base of instruments, but we're not exactly optimized for perfect performance, if you will, in terms of ease-of-use and having all of the right instruments.

    是的,至於器械方面,Larry,我會說——這與我們切入新市場與新手術目標的一貫做法相當一致:我們有一套不錯的器械基礎,但若要達到最佳化、也就是在易用性以及具備所有合適器械以達到理想表現方面,還沒有完全最佳化。

  • But think of it in terms of adding a few instruments rather than creating a whole new category of instruments. And I think that will be -- that's been consistent and will be consistent as we go into new procedure targets.

    但請把它想成是增加幾項器械,而不是創造一個全新的器械類別。我認為這將會——一直以來都一致,並且在我們進入新的手術標的時也會保持一致。

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • With regard to uses of cash, I'll turn that to Marshall.

    關於現金用途,我把這題交給 Marshall。

  • Marshall Mohr - SVP and CFO

    Marshall Mohr - SVP and CFO

  • Yes, so we bought back 343,000 shares this quarter. We have 383 million still authorized by the Board. We'll continue the program. We'll buy back stock when it makes sense; not a absolutely certain amount every day. Beyond that, the cash is there for investment back into the business over time, particularly if there were to be a extended or deepened economic issue on a macro basis, as well as for investment into IP as the opportunities come up.

    是的,所以我們本季回購了 343,000 股。董事會仍核准我們可回購的額度還有 3.83 億美元。我們會持續這個計畫。在合理的時候我們就會回購股票;不會每天都有一個絕對固定的回購量。除此之外,這些現金也會隨時間投入回到業務中,特別是如果宏觀層面出現延長或加深的經濟問題,以及在機會出現時投資於智慧財產權(IP)。

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • Or other technologies.

    或其他技術。

  • Marshall Mohr - SVP and CFO

    Marshall Mohr - SVP and CFO

  • Yes.

    是的。

  • Lawrence Keusch - Analyst

    Lawrence Keusch - Analyst

  • Okay, great. Thank you.

    好的,很棒。謝謝。

  • Operator

    Operator

  • David Roman, Goldman Sachs.

    David Roman,高盛。

  • David Roman - Analyst

    David Roman - Analyst

  • Thank you for taking the questions. I was hoping to focus a little bit on the spending side of the equation. Obviously, you had guided to the $20 million sequential uptick this quarter versus the second quarter.

    謝謝讓我提問。我希望把焦點稍微放在支出這一端。顯然,你們先前指引本季相較第二季將季增 2,000 萬美元。

  • But if I just looked at the income statement, SG&A is still being down as a percentage of sales year-over-year. So if you take out the options grant this quarter, can we maybe talk about your spending priorities? It sounds like you have a lot on deck here in terms of investing in new procedure categories, trying to fend off the assault on dVT; rebuilding your Euro presence, yet SG&A is still growing slower than revenue. That's -- and I have a follow-up.

    但如果我只看損益表,SG&A 佔銷售額的比重仍然是年對年下降。所以如果把本季的選擇權授予(options grant)排除掉,我們是否可以談談你們的支出優先順序?聽起來你們手上有很多事情要做,包括投資新的手術類別、試圖抵禦對 dVT 的攻勢、重建你們在歐洲的布局,但 SG&A 仍然比營收成長得慢。這——我還有一個追問。

  • Marshall Mohr - SVP and CFO

    Marshall Mohr - SVP and CFO

  • Yes, we've talked just on the numbers side and then I'll hand it over. We guided towards about $20 million increase in operating expenses quarter-to-quarter. It came in closer to $17.5 million. So a little bit less than that and I think it had a little bit to do with the timing here. We called out R&D projects last quarter. Some of those you're going to see probably spilling into future quarters.

    是的,我們先就數字面談一下,然後我再交給他。我們指引營業費用(OpEx)季對季增加約 2,000 萬美元。實際結果更接近 1,750 萬美元。所以比那個數字略低,我認為部分原因與時點有關。我們上季提到一些研發(R&D)專案。其中一些你們可能會看到延後到未來幾季。

  • And then I think the timing on SG&A that you allude to, David, we're starting on some things that we thought we might be -- might have been a little further along here in Q3, in terms of building the organization and the training capacities and so on. So, in terms of the numbers, I think the -- you're going to see some growth in the OpEx going forward into Q4, and that's inherent in the 40% operating income guidance we gave.

    另外,關於你提到的 SG&A 時點問題,David,我們正在啟動一些事項;原本我們以為在第三季(Q3)時可能會進展得更前面一些,像是組織建置、訓練能力等。所以就數字而言,我認為——你們會在往第四季(Q4)看到 OpEx 有一些成長,而這也已反映在我們給出的 40% 營業利益指引之中。

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • I think we've laid out for you the things that we think are deserving of differential or additional investment. We've typically been thoughtful about how we invest, and we don't trend to mad dash in one direction or another. And so we'll be building it out, but we'll build it out against plan.

    我想我們已經向各位說明了,我們認為哪些事項值得差異化或額外投資。我們一向在投資上很審慎,不會突然朝某個方向瘋狂衝刺。因此我們會逐步建置,但會依照計畫來建置。

  • David Roman - Analyst

    David Roman - Analyst

  • Okay. And then Japan, which has obviously been very successful for you, particularly since you got the reimbursement in April, can we maybe talk about the sort of sustainability of that business? You referenced, I think, in your prepared remarks that there is some spillover of the dVP concerns of the US into Europe. And obviously Japan is at a much more nascent stage in its ramp, so you probably wouldn't see it at this point. But any concerns on that transpiring in Japan, and how we should think about growth in that business over the next 12 months or so?

    好的。接著談日本,你們在那裡顯然非常成功,尤其是自從四月取得給付(reimbursement)之後;我們能否談談那項業務的可持續性?我記得你在事先準備的發言中提到,美國對 dVP 的一些疑慮有外溢到歐洲。而日本的成長爬坡仍在更早期階段,所以你們現在可能還看不到。但你們是否擔心同樣的情況會在日本發生?以及我們應該如何看待未來 12 個月左右該業務的成長?

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • On the dVP side, actually the uptake has been significant in terms of dVP in Japan relative to the number of prostatectomies that they do. We do denominate it in prostatectomies based on what they've been doing there.

    就 dVP 而言,實際上日本對 dVP 的採用率相當顯著,若以他們進行的前列腺切除術數量來看尤其如此。我們是以他們在當地進行的前列腺切除術為基礎來衡量。

  • We haven't heard a reflection of this set of concerns into Japan. It's not to say that it might not happen in the future. It might. In general, I think that Japanese surgeons have expressed interest in da Vinci for a pretty broad variety of procedures. So, even were that to be pressured over time, I don't know that it would dampen enthusiasm of -- for a long period for other procedures as we go. (multiple speakers) Quarter-to-quarter performance can be lumpy there.

    我們尚未聽到這一系列疑慮在日本有所反映。但這不代表未來不會發生。有可能會。整體而言,我認為日本外科醫師對達文西在相當廣泛的手術種類上都表達了興趣。因此,即便隨時間推移那一塊受到壓力,我也不認為它會在很長一段時間內削弱大家對其他手術的熱情,隨著我們持續推進。(多位發言者)那邊的季對季表現可能會有波動。

  • David Roman - Analyst

    David Roman - Analyst

  • Sure. And then maybe just one quick clarification question. From an EPS perspective this quarter, the $4.46 you reported includes that tax benefit that you discussed. Are you going to -- are you pointing people toward a non-GAAP number, or the GAAP $4.46 in terms of thinking about the ongoing earnings number for the quarter?

    了解。再來一個很快的釐清問題。就本季 EPS 而言,你們公布的 4.46 美元包含你們提到的那項稅務利益。你們是要引導大家看一個非 GAAP 的數字,還是以 GAAP 的 4.46 美元來思考本季的經常性獲利水準?

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • So we gave you the $4.46, which is the GAAP number; but we also said if you excluded that, we would have been at $3.54. So we're trying to provide you with all the information so that you can do your own comparisons.

    所以我們給你的是 4.46 美元,也就是 GAAP 數字;但我們也說過,如果排除那項因素,我們會是 3.54 美元。因此我們是希望提供你所有資訊,讓你可以自行做比較。

  • David Roman - Analyst

    David Roman - Analyst

  • Okay, thank you.

    好的,謝謝。

  • Operator

    Operator

  • Jeremy Feffer, Cantor Fitzgerald.

    Jeremy Feffer,Cantor Fitzgerald。

  • Jeremy Feffer - Analyst

    Jeremy Feffer - Analyst

  • Thanks for taking my question. I wanted to come back to your comments on this sales with simulators, Firefly, dual consoles. It seemed like sequentially those were down, even though total da Vinci sales were up sequentially. Is there anything to read into that? Are some customers looking at more de-featured units? Or is that just a complete coincidence?

    謝謝讓我提問。我想回到你們對於搭配模擬器、Firefly、雙控制台這些銷售的評論。看起來這些項目季比是下降的,儘管達文西總銷量季比上升。這有什麼需要解讀的嗎?是否有些客戶在看功能較精簡的機型?還是這只是完全的巧合?

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • Yes, it definitely trended down. I think on the Firefly side, though, it was pretty similar. We've been saying about the last three quarters that about half the US systems have gone out with Firefly configuration. And that held true in Q3.

    是的,確實呈現下降趨勢。不過就 Firefly 而言,其實相當類似。我們過去大約三季一直在說,美國出貨的系統約有一半採用 Firefly 配置。第三季(Q3)也維持如此。

  • As relates to the dual console and the simulator, those kind of go together in some respects, as they're, in large part, training tools and applications. And a slow downward trend there is something that we would have predicted internally here, as maybe a fair number of sites have invested in these technologies for training.

    至於雙控制台與模擬器,在某些方面是一起看的,因為它們在很大程度上是訓練工具與應用。而那裡出現緩慢的下滑趨勢,是我們內部原本就會預期的,因為可能已有相當多的據點投資了這些訓練技術。

  • And then, as you know, a lot of systems we sell now are to existing customers. And some of those existing customers already have simulators and dual consoles. So it's maybe less obvious value in those situations. So a little -- a downward trend there is probably something we would expect, but very gradual.

    另外,如你所知,我們現在賣出的許多系統是賣給既有客戶。而其中一些既有客戶已經有模擬器與雙控制台。所以在那些情況下,這些配備的價值就沒那麼明顯。因此那邊出現一些下滑趨勢大概是我們會預期的,但會非常緩慢。

  • Jeremy Feffer - Analyst

    Jeremy Feffer - Analyst

  • Okay. And quick follow-up on revenue per procedure, I heard the comments on timing of stocking and distributor orders, is this a run rate that we should be expecting now going forward? Obviously, it had been trending up with a lot of the new instruments. But with a lot of those now in there, is this more of a comfortable run rate?

    好的。再追問一下每例手術的營收(revenue per procedure),我聽到你們對備貨時點與經銷商訂單的說明;這是否是我們往後應該預期的常態水準(run rate)?顯然,之前隨著許多新器械推出而呈現上升趨勢。但現在其中很多都已經導入了,這是否更像是一個較為舒適的常態水準?

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • Yes, I mean we've been seeing the run-up, as you say, in recent quarters due to the impact of the new products. And what we've been saying, there are a lot of factors that can serve to move that metric up or down. And in this particular quarter, as Marshall called out in his commentary, we saw some of the timing of those initial stocking orders, with system sales and distributor orders, kind of serve to drive it slightly down here.

    是的,我的意思是,正如你所說,由於新產品的影響,我們在最近幾個季度確實看到該指標上升。而我們一直在說,有很多因素可能會使該指標上升或下降。在本季度,正如 Marshall 在他的評論中提到的,我們看到那些初期鋪貨訂單在時點上的一些影響,系統銷售與經銷商訂單在某種程度上使其在這裡略微下降。

  • But I'd say going forward, it could go up or down, depending. We also sell some of the product -- the procedure mix, right? So the more single sites and benign hysterectomies have a lower revenue per procedure for us kind of pushes it down. So, again, I'd say going forward, it could probably go either way from where we are right now.

    但我想展望未來,它可能上升也可能下降,取決於情況。我們也會銷售部分產品——手術組合(procedure mix),對吧?因此,單孔(single site)以及良性子宮切除術(benign hysterectomies)占比越高,對我們而言每例手術的收入較低,會在某種程度上把它往下拉。所以,再次強調,往後看,從我們目前的位置來看,它大概可能往任一方向變動。

  • Jeremy Feffer - Analyst

    Jeremy Feffer - Analyst

  • Okay. That's helpful. Thank you.

    好的。這很有幫助。謝謝。

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • That was our last question. As we have said previously, while we focus on financial metrics such as revenues, profits and cash flow during these conference calls, our organizational focus remains on increasing patient value by improving surgical outcomes, and reducing surgical trauma.

    這是我們最後一個問題。正如我們先前所說,雖然在這些電話會議中我們會聚焦於營收、利潤與現金流等財務指標,但我們組織的重點仍是透過改善手術結果來提升病患價值,並降低手術創傷。

  • I hope the following experience from Susan of Ohio gives you some sense of what this means in the lives of our patients. Quote -- "I was diagnosed in August of 2011 with adenocarcinoma. I'm a mom of five, grandma of 11, and 52 years old. I quit smoking years ago. Wow. I had a lot to think about when, by God's grace, I was introduced to a super surgeon.

    我希望以下來自俄亥俄州 Susan 的經驗,能讓各位對這在我們病患生活中的意義有所體會。引述——「我在 2011 年 8 月被診斷為腺癌(adenocarcinoma)。我是五個孩子的媽媽、11 個孫子的奶奶,52 歲。我多年前就戒菸了。哇。當我在上帝的恩典下被介紹給一位超級外科醫師時,我有很多事情要思考。」

  • "At the time, he thought I would be a really great candidate for the da Vinci robotic-assisted surgery. I figured it sounded really great. We did the surgery in December of 2011. At first, when I started reading about it on websites and talking with people, it sounded really scary. But after reading testimonies like mine, I realized it was the only way to go.

    「當時,他認為我會是達文西機器人輔助手術(da Vinci robotic-assisted surgery)的非常合適候選人。我覺得聽起來很棒。我們在 2011 年 12 月做了手術。一開始,當我在網站上閱讀相關資訊並與人交談時,聽起來真的很可怕。但在讀了像我這樣的見證之後,我意識到這是唯一的選擇。」

  • "And so, we removed the top lobe of my left lung in December of 2011. I was home in two days. The nurses at the hospital could not believe the type of surgery I'd had. Wow, how the robot changed my life. In no time, I was back to a normal life.

    「因此,我們在 2011 年 12 月切除了我左肺的上葉。我兩天就回家了。醫院的護理人員簡直不敢相信我做的是這種手術。哇,機器人如何改變了我的人生。沒多久,我就回到正常生活。」

  • "My surgeon is one of the best around and I am living proof. He saved my life, saved me from a grueling recovery, and saved me from a horrific scar. I had a few little holes and a small incision where they removed the lung. While they were in there, they took lymph nodes -- which, by the way, are great. No cancer and a 20% chance that this cancer comes back.

    「我的外科醫師是附近最棒的之一,而我就是活生生的證明。他救了我的命,讓我免於艱辛的復原過程,也讓我免於可怕的疤痕。我只有幾個小孔,以及一個取出肺部的小切口。他們在裡面時也取了淋巴結——順帶一提,結果很好。沒有癌症,而且這個癌症復發的機率是 20%。」

  • "If you're considering this type of surgery, I urge you to really think positively about this. Just absolutely amazing what modern medicine is all about. I would welcome the chance to have the surgery versus the old-fashioned way. Recovery was two weeks and I was back to work in three. It's a miracle that they can do these things with a robot, but they do." -- end quote.

    「如果你正在考慮這類手術,我敦促你真的要以正向的態度看待這件事。現代醫學到底是什麼,真是令人驚嘆。我很樂意選擇這種手術,而不是傳統方式。復原期是兩週,三週我就回去工作了。他們能用機器人做到這些,簡直是奇蹟,但他們確實做到了。」——引述結束。

  • Patients like these are our strongest advocates for da Vinci surgery, and form the very foundation of our operating performance. We've built our Company to take surgery beyond the limits of the human hand, and I assure you that we remain committed to driving the vital few things that truly make a difference.

    像這樣的病患是達文西手術最強而有力的倡議者,也構成我們營運表現最根本的基礎。我們打造公司,是為了讓手術突破人手的極限;我向各位保證,我們仍致力於推動那些真正能帶來改變的關鍵少數事項。

  • This concludes today's call. We thank you for your participation and support on this extraordinary journey to improve surgery. And we look forward to talking with you again in three months.

    今天的電話會議到此結束。感謝各位在這段改善手術的非凡旅程中參與並支持我們。我們期待三個月後再與各位交流。

  • Operator

    Operator

  • Thank you very much. And ladies and gentlemen, this conference call will be available for replay after 3.30 p.m. Pacific Time today, running through October 16, 2013, expiring at midnight. You may access the AT&T Executive Playback Service at any time by dialing 800-475-6701 and entering the access code of 259631. International parties may dial 320-365-3844. Once again, those phone numbers are 800-475-6701 and 320-365-3844, using the access code of 259631.

    非常感謝。各位女士、先生,本次電話會議將於今日太平洋時間下午 3:30 之後提供重播,並持續至 2013 年 10 月 16 日,於午夜到期。您可隨時撥打 800-475-6701 並輸入存取碼 259631,以使用 AT&T 高階主管重播服務(Executive Playback Service)。國際來電者可撥打 320-365-3844。再次提醒,電話號碼為 800-475-6701 與 320-365-3844,存取碼為 259631。

  • That does conclude your conference call for today. We do thank you for your participation and using AT&T's Executive Teleconference. You may now disconnect.

    今天的電話會議至此確實結束。我們感謝各位的參與,以及使用 AT&T 的高階主管電話會議服務(Executive Teleconference)。您現在可以掛線。